Inhaled steroids are recommended for long-term control of asthma, but their use may be limited in young children because of difficulties in using the associated inhaler device.The use of nebulizers may help to overcome this issue, without compromising therapeutic efficacy or safety.This I4-week, multicentre, randomized, controlled, open-label, parallelgroup study compared the efficacy and safety of nebulized corticosteroids in paediatric patients (aged 6 months to 6 years) with severe persistent asthma. Beclometasone dipropionate (BDP) 800 pg day' suspension for nebulization and budesonide (BUD) 750 pgdayl given by nebulization in a twice-daily regimen, and when used in addition to the usual maintenance therapy, resulted in comparable clinical efficacy across all parameters.The primary efficacy endpoint was the number of patients who did not experience any major exacerbation, this being 40.4% and 5 I .7% in the BDP and BUD groups respectively in the ITT population (P=O.28), and the mean number of global exacerbations (major plus minor) decreased respectively by -37.5% in the BDP group and -23.3% in the BUD group. Both treatments were also associated with marked reductions in the number of nights with wheezing and the number of days of oral steroid use. Moreovev; the two treatment groups had a similar adverse-event incidence and profile. Only I I adverse events were reported, and no serious adverse events were related to treatment. Urinary cotiisol and the time course of height and weight were unaffected by both treatments, and BDP was confirmed to have a neutral effect on bone metabolism. In conclusion, this study demonstrates that both BDP 800 pgdayl suspension for nebulization and BUD 750 pgda)rl administered by nebulization are effective, with an acceptable safety profile, for treatment of severe persistent asthma in infants and young children.
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INTRODUCTION
Despite the growing knowledge of the pathogenesis of asthma, the prevalence of this disease appears to be on the increase. Indeed, asthma is now the most common chronic disease amongst children, affecting some 5-l 0% of children under the age of 6 years: around 10% of asthmatic children develop symptoms before the age of I year, and over 50% by the age of 2 years.
The prevention of long-term respiratory complications associated with asthma is based on early and adapted management of the condition, in particular by using antiinflammatory therapy as early as possible. Furthermore, were the number of major plus minor exacerbations, the time to onset of the first major exacerbation, the number of nebulizations or inhalations of salbutamol, the mean duration of oral steroid therapy, the number of days and nights with wheezing and with cough, and parental absenteeism from work due to child disease.The primary safety evaluation parameter in the study was the concentration of urinary deoxypyridinoline measured by ELISA and expressed by the urinary deoxypyridinoline:
urinary creatinine ratio, to determine the effect of the steroid treatments on bone resorption. Secondary safety criteria included the cortisol: creatinine ratio in the first morning urine sample, height and weight gains between visits 2 and 5, and adverse events reported by the parents. Clinical safety was assessed at each visit during the study. 
RESULTS

Patient population
Of the I30 patients (mean age 2. I + I .4 years) screened for the study in 24 centres, 120 were randomized to treatment:
58 to BDP, and 62 to BUD.The number of major exacerbations after visit 2 was not available for three patients (one in the BDP group and two in the BUD group), who were then eliminated from the ITT population, and I8 patients (five in the BDP group and I3 in the BUD group) presented at least one major protocol violation. In total, therefore, I I7 patients were analysed in the ITT population (57 treated with BDP and 60 with BUD) and 99 in the PP population (52 treated with BDP and 47 with BUD). The groups were homogeneous in terms of demographic characteristics at selection (Table I) Time to onset of the first major exacerbation. ITT population. exacerbation was 46.3 days for BDP patients vs 46. I days for BUD patients, with no difference evident between the two groups (PzO.72) ( Figure I ).
The two treatment groups were subsequently found to have produced a significant and similar reduction in the number of exacerbations (major + minor) per patient per day between the run-in and treatment periods: down by 37.5% for the BDP group and by 23.3% for the BUD group (P=O*60) (Table 3) .
Both BDP and BUD produced particularly marked effects with respect to the mean number of days of oral steroid therapy, with significant reductions of 66.7% for the BDP group (P~O.002) and 58.3% for the BUD group (P=O*OO7) (Figure 2) . No significant differences were found between the groups for the randomized treatment period (P=O. 19).
The mean number of nebulizations or inhalations of salbutamol varied significantly during the study, with significant reductions of 61.8% for the BDP group (P<O*OOO I) and 57.8% for the BUD group (P<O*OOOl), and were similar for the two groups during the treatment period (PzO.22) (Figure 3 ). The mean number of days with wheezing varied significantly during the study, with significant reductions of 53. I % for the BDP group (P=O*OO I) and 64.3% for the significant for the entire randomized treatment period the BDP and BUD groups also had similar increases in (P=O*23). bodyweight and height during the study. The mean number of nights with cough also varied considerably during the study, with significant reductions of 55.6% for the BDP group (P<O.OOOl) and 45.5% for the BUD group (kO.004).
No significant difference was found between the two treatments (P=O*O7). Finally, according to patient and investigator assessments of treatment, some 40-5 I% of patients considered treatment with either BDP or BUD to be 'good' or 'very good' at treatment end in both the ITT and PP populations.
Evaluation of safety
Assessment of clinical safety of the two treatments was based on I30 subjects. There was no change in bone metabolism, as indicated by a static urinary deoxypyridinoline : urinary creatinine ratio, for either group (Table 4) . Urinary cortisol and urinary cortisolkreatinine ratios were not significantly affected during treatment for both the BDP and BUD groups (Table 5) . Patients in In total, 4 I7 emergent adverse effects were reported during the study, 79 of which occurred in the run-in phase and 338 in the randomized treatment period. Of the 338 adverse events observed in the randomized treatment period, 168 were reported in the BDP group and 170 in the BUD group. However, only I I adverse events in total (five in the BDP group and six in the BUD group) were considered to be treatment-related. Furthermore, none of the I6 serious adverse events reported by I4 patients during the study (eight adverse events and seven patients in each group) were found to be related to treatment.
Overall, the frequency and profile of adverse events were equivalent for the two treatments, with side-effects generally being associated with the ear, nose, and throat, and respiratory system.
DISCUSSION
Inhaled steroid therapy is recommended for the longterm control of asthma in children (3). However, some young children may experience co-ordination and/or inspiratory difficulties when using available MDls or DPls and in such instances nebulization may be useful since this method of administration requires minimum cooperation.
Indeed, the efficacy of steroid therapy, namely BUD, given via nebulization as a basic treatment for infants and children with asthma has been confirmed in a number of studies undertaken to date (4-8). This present study was to designed to compare the efficacy and safety of BDP suspension for nebulization with those of BUD, both given via a nebulizer as a l2-week treatment for severe persistent asthma in infants and children.
The results of the study demonstrated that nebulized forms of BDP and BUD had similar effects with regard to the various efficacy criteria assessed, which included asthma exacerbations (major and minor) and symptoms, and the use of rescue medication.The results were not biased for separation between major and minor exacerbations since no difference was demonstrated during a post-hoc analysis of total exacerbations. Both treatments had a particularly notable effect in reducing the number of nights of wheezing and days of oral steroid use. Furthermore, a similar adverse-event profile was reported for the two treatments. Efficacy was primarily assessed by the incidence of major and minor exacerbations during the treatment period, analysed separately. These two parameters were defined as bronchodilator treatment failure associated with a non-planned physician visit for minor exacerbations, and bronchodilator treatment failure associated with a non-planned physician visit plus oral steroid prescription for major exacerbations.
Oral steroid prescriptions are mainly dependent on physician habit and could vary significantly from one physician to another.As major and minor exacerbations differ only by the prescription of oral steroids, it was logical to pool them in a post-hoc analysis to explore an overall parameter termed 'nonplanned physician visit' which is a very important parameter for the follow-up of asthmatic children.The results of this analysis are shown in The results of this study support the clinical use of BDP 800 pg day' suspension for nebulization for the treatment of infants and young children with severe persistent asthma. BDP suspension for nebulization is as safe and clinically effective as nebulized BUD and appears to be a suitable and valuable therapeutic alternative for asthma in this young patient population.
